Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 9/20 | 0.49 |
| ▸ | CTSK | P43235 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236231 | 0.88 | CTSK (0.54) | HRH3CTSSCTSKKCNH2CTSB | |
| SCHEMBL3878368 | 0.84 | CTSK (0.49) | HRH3CTSSCTSKKCNH2HRH4 | |
| SCHEMBL3873562 | 0.82 | CTSK (0.52) | HRH3CTSSCTSKKCNH2HRH4 | |
| SCHEMBL16013563 | 0.82 | PRKD1 (0.47) | HRH3HRH4HTR1AADRA2AADRA2C | |
| SCHEMBL30085868 | 0.81 | CTSK (0.48) | CTSSCTSKKCNH2CTSB | |
| SCHEMBL28895224 | 0.81 | CTSK (0.48) | CTSSCTSKKCNH2CTSB | |
| SCHEMBL28895222 | 0.81 | CTSK (0.48) | CTSSCTSKKCNH2CTSB | |
| SCHEMBL3873575 | 0.81 | CTSK (0.51) | HRH3CTSSCTSKKDM2B | |
| Hydrochloric Acid SCHEMBL3885789 | 0.80 | CTSK (0.50) | HRH3CTSSCTSKKDM2B | |
| SCHEMBL25460017 | 0.79 | CTSS (0.48) | CTSSCTSKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928842-B1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2009-11-18 | — | — | EP | claimed |
| EP-1928842-A1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2008-06-11 | — | — | EP | claimed |
| US-7326715-B2 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2008-02-05 | — | — | US | claimed |
| US-20070111992-A1 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | claimed |
| WO-2007039470-A1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | claimed |
| CN-101268058-B | 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | MSD OSS BV | 2013-02-27 | — | — | CN | disclosed |
| EP-1928842-B1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2009-11-18 | — | — | EP | disclosed |
| EP-1928842-A1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2008-06-11 | — | — | EP | disclosed |
| US-7326715-B2 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2008-02-05 | — | — | US | disclosed |
| US-20070111992-A1 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039470-A1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111992-A1 | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives | CTSK, CTSS, CTSF | HRH3 973/4885CTSS 2/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.